Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: KVUE )

23.27 +0.14 (+0.63%)
Streaming Delayed Price Updated: 10:27 AM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 986,780
Open 23.14
Bid (Size) 23.27 (15)
Ask (Size) 23.28 (44)
Prev. Close 23.13
Today's Range 23.03 - 23.32
52wk Range 17.67 - 23.55
Shares Outstanding N/A
Dividend Yield 0.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
There are signs that NYSE:KVUE may be ready to breakout.
KENVUE INC is setting up nicely for a breakout. 
Via Chartmill
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga

Performance

YTD
+7.90%
+7.90%
1 Month
+6.18%
+6.18%
3 Month
+26.36%
+26.36%
6 Month
+8.46%
+8.46%
1 Year
+15.11%
+15.11%

More News

Read More
Analyst Ratings For Kenvue
Via Benzinga
Kenvue Drives Climate Action Strategy Forward
From Kenvue
Via Business Wire
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Via Benzinga
Decoding 5 Analyst Evaluations For Kenvue
Via Benzinga
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Donald Trump Owns These 21 Dividend Kings. Should You?
Via The Motley Fool
Topics Government
Exposures Political
Kenvue Announces Participation in the Barclays Global Consumer Staples Conference
From Kenvue
Via Business Wire
A Big CEO Move, Big Buffett Buys, and More
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Via The Motley Fool
Topics ETFs
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
7 Stable Dividend Stocks to Scoop Up on Discount
Via InvestorPlace
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
Via The Motley Fool
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
Via Talk Markets
Topics Stocks
Exposures US Equities
The 7 Best Under $20 Stocks to Buy in August 2024
Via InvestorPlace
Kenvue (KVUE) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Kenvue News: Why Investors Are Loving KVUE Stock This Week
Via InvestorPlace
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
KVUE Stock Earnings: Kenvue Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Listerine-Maker Kenvue's Stock Soars On Strong Q2 Sales From Its Essential Health Unit, Reaffirms Annual Guidance
Via Benzinga
Kenvue Reports Second Quarter 2024 Results
From Kenvue
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.